Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHILL-S: Hibernation-Like Therapy in Acute Ischemic Stroke
NCT07364344Phase 1Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of Aminazin and promethazine in ischemic stroke (4 arms). Primary endpoint: Dose-Limiting Toxicity and Maximum Tolerated Dose at 7 days. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
Aminazinpromethazine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07364344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364344.